Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri

Pehmen Yasin ÖZCAN, (Çocuk Hastalıkları Hastanesi, Göz Kliniği, Şanlıurfa, Türkiye)
Mehmet ÇITIRIK, (Ankara Ulucanlar Göz Eğitim ve Araştırma Hastanesi, Ankara, Türkiye)
Şehnaz ÖZÇALIŞKAN (SB Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye)
Retina-Vitreus
0 0
Yıl: 2016 Cilt: 24 Sayı: 4 Sayfa Aralığı: 263 - 270 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri

Öz:
Prematüre retinopatisi (PR) sadece prematüre infantlarda, çocukluk çağında retina dokusunda anormal fibrovasküler çoğalma ile ortaya çıkan önlenebilir körlüğün en önemli nedenlerinden biridir. Düşük doğum haftası ve doğum ağırlığı PR için bilinen en önemli risk faktörleridir. Günümüzde PR ile ilişkili görmeyi tehdit eden komplikasyonların sayısı; PR patofizyolojisi, yeni tarama araçları ve yeni tedavi seçenekleri sayesinde düşürülmüştür. Bu yazıda, PR gelişiminde altta yatan mekanizmanın daha iyi anlaşılabilmesi için güncel epidemiyoloji, patofizyoloji ve risk faktörleri ele alınmıştır.
Anahtar Kelime:

Konular: Göz Hastalıkları

Current Epidemiology, Pathophysiology, and Risk Factors in Retinopathy of Prematurity

Öz:
Retinopathy of prematurity (ROP) is one of the leading cause of preventable childhood blindness associated with abnormal retinal fibrovascular proliferation taking place only in premature infants. Low gestational age and birth weight are the main known risk factors for ROP. Nowadays, the numbers of sight-threatening complications associated with ROP have been reduced by understanding pathophysiology of ROP, new screening tools, and novel treatment options. In this review, the current epidemiology, pathophysiology, and risk factors of ROP have been evaluated to better understand underlying mechanisms of ROP.
Anahtar Kelime:

Konular: Göz Hastalıkları
Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Bibliyografik
  • Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: (1) preliminary report. Am J Ophthalmol 1942;25:203-4.
  • Niranjan HS, Benakappa N, Reddy KR, et al. Retinopathy of PrematurityPromising Newer Modalities of Treatment. Indian Pediatrics. 2012;49:139-43.
  • Patz A. The role of oxygen in retrolental fibroplasia. Trans Am Ophthalmol Soc. 1968;66:940-985.
  • Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol.1954;38:397-432.
  • Gergely K, Gerinec A. Retinopathy of prematurity--epidemics, incidence, prevalence, blindness. Bratisl Lek Listy. 2010;111:514-7.
  • Fleck B. Opthalmology. In: Rennie JM, ed. Rennie and Robertson's Textbook of Neonatology. 5th ed. London: Churchill Livingstone Elsevier; 2012:837-848.
  • Askin DF, Diehl-Jones W. Retinopathy of prematurity. Crit Care Nurs Clin North Am. 2009;21:213-33.
  • Quimson SK. Retinopathy of Prematurity: Pathogenesis and Current Treatment Options. Neonatal Netw. 2015;34:284-7.
  • Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013;131:189-95.
  • Lawn JE, Gravett MG, Nunes TM, et al. GAPPS Review Group. Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010;10:S1
  • Liu L, Johnson HL, Cousens S, et al. for the Child Health Epidemiology Reference Group of WHO, UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151-61.
  • Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445-57.
  • Bas AY, Koc E, Dilmen U; ROP Neonatal Study Group. Incidence and severity of retinopathy of prematurity in Turkey. Br J Oph- thalmol 2015;99:1311-4.
  • Ozcan PY, Con R, Celik HT. [Incidence, risk factors and treatment outcomes of retinopathy of prematurity in the southeastern Anatolian region province of Şanlıurfa in Turkey]. Turkiye Klinikleri J Med Sci 2015;35:240-7.
  • Öner A, Özkırış A, Güneş T. [Retinopathy of prematurity: screening resluts for 2 years]. Erciyes Tıp Dergisi 2005;27:104-9.
  • Özcan E, Yenice Ö, Kazokoğlu H, et al. [The incidence and risk fac- tors that play role in development of retinopathy of prematurity in premature babies]. Ret-Vit 2006;14:127-32.
  • Hanedar A, Göncü T, Adıbelli FM, et al. [Screening And Treatment Results Of Retinopathy Of Prematurity]. Harran Üniversitesi Tıp Fakültesi Dergisi (Journal of Harran University Medical Faculty). 2015;12: 274-280.
  • Demir S, Yücel ÖE, Niyaz L, et al. Incidence of retinopathy of prematurity in the middle Black Sea region of Turkey over a 10-year period. J AAPOS 2015;19:12-5.
  • Austeng D, Källen KB, Ewald UW, et al. Incidence of retinopathy of prema- turity in infants born before 27 weeks gestation in Sweden. Arch Ophthal- mol. 2009;127:1315-19.
  • Markestad T, Kaaresen PI, Rİnnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics. 2005;115:1289-98.
  • Michaelson IC. The mode of development of the vascular system of the re- tina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K;.68:137-180.
  • Chan-Ling T, McLeod DS, Hughes S,et al. Astrocyte-endothelial cell relati- onships during human retinal vascular development. Invest Ophthalmol Vis Sci 2004;45:2020-32.
  • McLeod DS, Hasegawa T, Prow T, et al. The initial fetal human retinal vas- culature develops by vasculogenesis. Dev Dyn 2006;235:3336-47.
  • Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal reti- na: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci. 2000;41:1217-28.
  • Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEBF is a significant contri- butor to retinal neovascularization. J Pathol 2009;219:446-54.
  • Jiang Y, Wang H, Culp D, et al. Targeting Muller cellederived VEBF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:824-31.
  • Rivera JC, Sapieha P, Joyal JS, et al. Understanding retinopathy of prematu- rity: update on pathogenesis. Neonatology 2011;100:343-53.
  • Hartnett ME. Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity. Ophthalmology. 2015;122:200-210.
  • Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-11.
  • Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Pre- maturity. N Engl J Med. 2012;367:2515-2526.
  • Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hype- roxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994;36:724-31.
  • Penn JS, Henry MM, Wall PT, et al. The range of PaO2 variation determines the severity of oxygen induced retinopathy in newborn rats. Invest Ophthal- mol Vis Sci. 1995;36:2063-70.
  • Wang H, Smith GW, Yang Z, et al. Short hairpin RNA-mediated knockdown of VEBFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. Am J Pathol 2013;183:964-74.
  • Wang H, Yang Z, Jiang Y, et al. Quantitative analyses of retinal vascular area and density after different methods to reduce VEBF in a rat model of retino- pathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:737-44.
  • Lutty GA, McLeod DS, Bhutto I, et al. Effect of VEBF Trap on normal retinal vascular development and oxygen- induced retinopathy in the dog. Invest Ophthalmol Vis Sci 2011;52:4039-47.
  • Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med. 2012; 17:26-29.
  • Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Frontiers in bioscience: a journal and virtual library. 2003;8:d1030-43.
  • Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decrea- ses vascular stability in mice. J Clin Invest. 2008;118:526-33.
  • Chen J, Connor KM, Aderman CM, et al. Suppression of retinal neovascu- larization by erythropoietin siRNA in a mouse model of proliferative retino- pathy. Invest Ophthalmol Vis Sci. 2009;50:1329-35.
  • Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/ vascular permeability factor expression in a mouse model of retinal neovas- cularization. Proc Natl Acad Sci USA. 1995;92:905-09.
  • Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-28.
  • Hellström A, Engström E, Hård AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016-20.
  • Connor KM, Sangiovanni JP, Löfqvist C, et al. Increased dietary intake of omega-3- polyunsaturated fatty acids reduces pathological retinal angioge- nesis. Nat Med. 2007;13:868-73.
  • Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovasculari- zation in vivo by inhibition of vascular endothelial growth factor (VEBF) using soluble VEBF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-61.
  • Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-92.
  • Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res. 2010;86:236-42.
  • Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-82.
  • Budd S, Byfield G, Martiniuk D, et al. Reduction in endothelial tip cell filo- podia corresponds to reduced intravitreous but not intraretinal vascularizati- on in a model of ROP. Exp Eye Res. 2009;89:718-27.
  • Geisen P, Peterson LJ, Martiniuk D, et al. Neutralizing antibody to VEBF reduces intravitreous neovascularization and does not interfere with vascu- larization of avascular retina in a rat model of retinopathy of prematurity. Mol Vis. 2008;14:345-57.
  • McColm JR, Geisen P, Hartnett ME. VEBF isoforms and their expres- sion after a single episode of hypoxia or repeated fluctua- tions between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis [serial online] 2004;10:512-20.
  • Hartnett ME. Studies on the pathogenesis of avascular retina and neovascu- larization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthal- mological Society thesis). Trans Am Ophthalmol Soc 2010;108:96-119.
  • Budd S, Byfield G, Martiniuk D, et al. Reduction in endothelial tip cell filo- podia corresponds to reduced intravitreous but not intraretinal vascularizati- on in a model of ROP. Exp Eye Res 2009;89:718-27.
  • Hartnett ME, Martiniuk D, Byfield G, et al. Neutralizing VEBF decreases tortuosity and alters endothelial cell division orien- tation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 2008;49:3107-14.
  • Wang H, Byfield G, Jiang Y, et al. VEBF-mediated STAT3 activation in- hibits retinal vascularization by down-regulating erythropoietin expression. Am J Pathol. 2012;180:1243-53.
  • Ueki Y, Wang J, Chollangi S, et al. STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage. J Neurochem. 2008;105:784-96.
  • Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematu- rity. Invest Ophthalmol Vis Sci. 1996;37:290-9.
  • Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-82.
  • Yang Z, Wang H, Jiang Y, et al. VEBFA activates erythropoietin receptor and enhances VEBFR2- mediated pathological angiogenesis. Am J Pathol 2014;184:1230-9.
  • Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006:CD004865.
  • Fowden AL. The insulin-like growth factors and feto-placental growth. Pla- centa. 2003;24:803-12.
  • Demendi C, Börzsönyi B, Nagy ZB, et al. Gene expression patterns of in- sulin-like growth factor 1, 2 (IGF-1, IGF-2) and insulin-like growth fac- tor binding protein 3 (IGFBP-3) in human placenta from preterm delive- ries: influence of additional factors. Eur J Obstet Gynecol Reprod Biol. 2012;160:40-44.
  • Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997; 276:1706-9.
  • Hellström A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEBF-survival signaling in retinal endothelial cells: direct correlation with clinical retino- pathy of prematurity. Proc Natl Acad Sci U S A. 2001; 98:5804-8.
  • Smith LE, Hard AL, Hellström A. The biology of retinopathy of Prema- turity: How Knowledge of Pathogenesis Guides Treatment. Clin Perinatol 2013;40:201-214
  • Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177:2715-23.
  • Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390-5.
  • Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinopathy thro- ugh suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007;104:10589-94.
  • Lofqvist C, Engström E, Sigurdsson J, et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin- like growth factor-1 deficit. Pediatrics. 2006;117:1930-8.
  • Hansen-Pupp I, Hövel H, Hellström A, et al. Postnatal decrease in circu- lating insulin-like growth factor-I and low brain volumes in very preterm infants. J Clin Endocrinol Metab. 2011;96:1129-35.
  • Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008; 49:5177-82.
  • Sapieha P, Stahl A, Chen J, et al. 5-Lipoxygenase Metabolite 4-HDHA Is a Mediator of the Antiangiogenic Effect of {omega}-3 Polyunsaturated Fatty Acids. Sci Transl Med. 2011;3:69ra12.
  • Penn JS, Tolman BL, Bullard LE. Effect of a water-soluble vitamin E ana- log, Trolox C, on retinal vascular development in an animal model of retino- pathy of prematurity. Free Radic Biol Med. 1997;22:977-84.
  • Neu J, Afzal A, Pan H, et al. The dipeptide Arg-Gln inhibits retinal neo- vascularization in the mouse model of oxygeninduced retinopathy. Invest Ophthalmol Vis Sci. 2006;47:3151-5.
  • Wikstrand MH, Hard AL, Niklasson A, et al. Maternal and neonatal factors associated with poor early weight gain and later retinopathy of prematurity. Acta Paediatr. 2011;100:1528-33.
  • The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxy- gen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomi- zed, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295-310.
  • Hauspurg AK, Allred EN, Vanderveen DK, et al. Blood gases and retino- pathy of prematurity: The ELGAN Study. Neonatology. 2011;99:104-11.
  • SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Ne- onatal Research Network, Carlo WA, Finer NN, Walsh MC, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362:1959-69.
  • Finer NN, Carlo WA, Walsh MC, et al. Early CPAP versus Surfactant in Extremely Preterm Infants. N Eng J Med. 2010;362:1970-9.
  • Stenson B, Brocklehurst P, Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Eng J Med. 2011;364:1680-82.
  • Hartnett ME, Lane RH. Effects of oxygen on the development and severity of retinopathy of prematurity. J AAPOS. 2013;17:229-34.
  • Askie LM. Optimal oxygen saturations in preterm infants: A moving target. Curr Opin Pediatr. 2013;25:188-92.
  • Darlow BA, Hutchinson JL, Henderson-Smart DJ, et al. for the Australian and New Zealand Neonatal Network. Prenatal risk factors for severe retino- pathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005; 115:990-96.
  • Austeng D, Blennow M, Ewald U, et al.The EXPRESS Group. Incidence of and risk factors for neonatal morbidity after active perinatal care: ext- remely preterm infants study in Sweden (EXPRESS). Acta Paediatr. 2010; 99:978-92.
  • Dhaliwal CA, Fleck BW, Wright E, et al. Retinopathy of prematurity in small- for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed. 2009; 94:F193-95.
  • Mittal M, Dhanireddy R, Higgins RD. Candida sepsis and association with retinopathy of prematurity. Pediatrics. 1998; 101(4 Pt 1):654-7.
  • Manzoni P, Maestri A, Leonessa M, et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol. 2006; 26:23-30.
  • Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med. 2012;17:26-9.
  • Chen M, Citil A, McCabe F, et al. Infection, oxygen, and immaturity: interac- ting risk factors for retinopathy of prematurity. Neonatology. 2011; 99:125-32.
  • Mitra S, Aune D, Speer CP, et al. Chorioamnionitis as a risk factor for Re- tinopathy of Prematurity: A systematic Review and Meta-Analysis. Neona- talogy. 2014;105:189-199.
  • Dammann O. Inflammation and retinopathy of prematurity. Acta Paediatr. 2010; 99:975-77.
  • Halimic JA, Zvizdic D, Halilovic EA, et al. Risk factors for retinopathy of prematurity in premature born children. Med Arh. 2015;69:409-413.
  • Thomas K, Shah PS, Canning R, et al. Retinopathy of prematurity: Risk factors and variability in Canadian neonatal intensive care units. J Neonatal Perinatal Med. 2015;8:135-8.
  • Slidsborg C, Jensen A, Forman JL, et al. Neonatal Risk Factors for Tre- atment-Demanding Retinopathy of Prematurity: A Danish National Study. Ophthalmology. 2016 ;123:796-803.
  • Aisen ML, Bacon BR, Goodman AM, et al. Chester EM. Retinal abnormali- ties associated with anemia. Arch Ophthalmol. 1983;101:1049-52.
  • Gomella TL, Cunningham MD, Eyal FG, eds. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. 6th ed. New York, NY: McGraw-Hill; 2009.
APA ÖZCAN P, CITIRIK M, OZCALISKAN S (2016). Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. , 263 - 270.
Chicago ÖZCAN Pehmen Yasin,CITIRIK Mehmet,OZCALISKAN SEHNAZ Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. (2016): 263 - 270.
MLA ÖZCAN Pehmen Yasin,CITIRIK Mehmet,OZCALISKAN SEHNAZ Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. , 2016, ss.263 - 270.
AMA ÖZCAN P,CITIRIK M,OZCALISKAN S Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. . 2016; 263 - 270.
Vancouver ÖZCAN P,CITIRIK M,OZCALISKAN S Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. . 2016; 263 - 270.
IEEE ÖZCAN P,CITIRIK M,OZCALISKAN S "Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri." , ss.263 - 270, 2016.
ISNAD ÖZCAN, Pehmen Yasin vd. "Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri". (2016), 263-270.
APA ÖZCAN P, CITIRIK M, OZCALISKAN S (2016). Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. Retina-Vitreus, 24(4), 263 - 270.
Chicago ÖZCAN Pehmen Yasin,CITIRIK Mehmet,OZCALISKAN SEHNAZ Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. Retina-Vitreus 24, no.4 (2016): 263 - 270.
MLA ÖZCAN Pehmen Yasin,CITIRIK Mehmet,OZCALISKAN SEHNAZ Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. Retina-Vitreus, vol.24, no.4, 2016, ss.263 - 270.
AMA ÖZCAN P,CITIRIK M,OZCALISKAN S Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. Retina-Vitreus. 2016; 24(4): 263 - 270.
Vancouver ÖZCAN P,CITIRIK M,OZCALISKAN S Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri. Retina-Vitreus. 2016; 24(4): 263 - 270.
IEEE ÖZCAN P,CITIRIK M,OZCALISKAN S "Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri." Retina-Vitreus, 24, ss.263 - 270, 2016.
ISNAD ÖZCAN, Pehmen Yasin vd. "Prematüre Retinopatisinde Güncel Epidemiyoloji, Patofizyoloji ve Risk Faktörleri". Retina-Vitreus 24/4 (2016), 263-270.
Sayfa Oluşturulma Tarihi
23-04-2024 0:58

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları